文献速递消化系统肿瘤

韩国胰腺癌治疗模式与生存结局趋势:一项全国性基于人群的研究

Trends in treatment patterns and survival outcomes in pancreatic cancer: A nationwide population-based study in Korea.
PubMed 文献 · Eur J Cancer · 2023-06-01

该研究利用韩国国民健康保险数据库,提取2006至2019年确诊的78,920例胰腺癌患者数据,分析不同年龄组和诊断年份的治疗模式与生存。结果显示,手术和化疗比例随时间逐渐增加,常用药物从吉西他滨±厄洛替尼转向吉西他滨+白蛋白结合型紫杉醇和FOLFIRINOX。所有患者中位总生存从2006-2008年的5.5个月改善至2018-2019年的9.8个月,年轻年龄组改善更明显。

要点

  • 2006-2019年韩国胰腺癌患者中,50.7%仅接受支持治疗,21.0%手术,26.6%化疗。
  • 手术和化疗比例在所有年龄组随时间逐渐增加。
  • 中位总生存从5.5个月改善至9.8个月,年轻组改善更明显。

核心结论

  • 胰腺癌手术和化疗率增加,过去十年生存率总体改善,接受手术或化疗者及年轻年龄组改善更明显。

研究设计与样本

  • 全国性基于人群的研究,利用韩国国民健康保险数据库,提取2006至2019年确诊的78,920例胰腺癌患者数据。

主要发现

  • 16,562例(21.0%)接受手术,20,998例(26.6%)接受化疗,1,332例(1.7%)接受放化疗,40,040例(50.7%)仅接受支持治疗。
  • 手术或化疗比例在所有年龄组随时间逐渐增加。
  • 常用抗癌药物从吉西他滨±厄洛替尼变为吉西他滨+白蛋白结合型紫杉醇和FOLFIRINOX。
  • 所有患者中位总生存从2006-2008年的5.5个月改善至2018-2019年的9.8个月。
  • 中位总生存改善幅度:≤59岁从8.8个月至18.8个月,60-69岁从6.8个月至14.6个月,70-79岁从4.2个月至8.3个月,≥80岁从2.4个月至3.4个月(所有p < 0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The treatment of pancreatic cancer has evolved; however, real-world data on treatment trends remain scarce. This study investigated treatment patterns for pancreatic cancer and patient survival using a nationwide population-based study in Korea. METHODS: Using the National Health Insurance database, data from 78,920 patients diagnosed with pancreatic cancer in Korea between 2006 and 2019 were extracted. Treatment patterns and survival by age group and year of diagnosis were examined. RESULTS: Primary treatment was delivered as follows: 16,562 patients (21.0%) underwent surgery, 20,998 patients (26.6%) received chemotherapy, 1332 patients (1.7%) received chemoradiotherapy, and 40,040 patients (50.7%) received supportive care only. The proportion of patients undergoing surgery or chemotherapy increased gradually in all age groups over time. The commonly used anti-cancer drugs have changed from gemcitabine±erlotinib to gemcitabine+nab-paclitaxel and FOLFIRINOX. Survival improved mainly in patients who underwent surgery or chemotherapy. Median overall survival for all patients improved from 5.5 months in 2006-2008 to 9.8 months in 2018-2019, with greater improvement observed in younger age groups: 8.8-18.8 months, age ≤59 years, 6.8-14.6 months, age 60-69 years, 4.2-8.3 months, age 70-79 years and 2.4-3.4 months, age ≥80 years (all p < 0.0001). CONCLUSIONS: An increase in the rates of surgery and chemotherapy for pancreatic cancer was observed. Survival rates for pancreatic cancer have generally improved over the past decade and are greater in patients undergoing surgery or chemotherapy and in younger age groups.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Park BK, Seo JH, Han JH, et al. Trends in treatment patterns and survival outcomes in pancreatic cancer: A nationwide population-based study in Korea. Eur J Cancer. 2023. PMID: 37352643. doi:10.1016/j.ejca.2023.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。